Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2011-9-15
pubmed:abstractText
Pruritus is a common symptom in systemic sclerosis (SSc), an autoimmune disease which causes fibrosis and vasculopathy in skin, lung, and gastrointestinal tract (GIT). Unfortunately, pruritus has limited treatment options in this disease. Pilot trials of low-dose naltrexone hydrochloride (LDN) for pruritus, pain, and quality of life (QOL) in other GIT diseases have been successful. In this case series we report three patients that had significant improvement in pruritus and total GIT symptoms as measured by the 10-point faces scale and the University of California Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 (UCLA SCTC GIT 2.0) questionnaire. This small case series suggests LDN may be an effective, highly tolerable, and inexpensive treatment for pruritus and GIT symptoms in SSc.
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:issn
1687-9279
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
2011
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
804296
pubmed:year
2011
pubmed:articleTitle
Low-dose naltrexone for pruritus in systemic sclerosis.
pubmed:affiliation
Division of Rheumatology, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132, USA.
pubmed:publicationType
Journal Article